Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study

Authors:
  • WHWasim Hanif
    Wasim Hanif
  • WMWaqar Malik
    Waqar Malik
  • AKAli Kamal
    Ali Kamal
  • PGParnia Geransar
    Parnia Geransar
  • NLNicola Lister
    Nicola Lister
  • CAChris Andrews
    Chris Andrews
  • ABAnthony Barnett
    Anthony Barnett

Abstract
Objective:To compare the incidence of hypoglycaemic events (HEs) in a real-world setting in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.Research design and methods:We performed a ≤16-week prospective, non-interventional, two-cohort study. Data were collected 1–6 weeks before and ≤6 weeks after fasting. Patients were enrolled who had been receiving vildagliptin (50 mg twice daily) or sulphonylurea (SU) as add-on to metformin at least 4 weeks prior to fasting.Main outcome measures:The primary efficacy endpoint was incidence of HEs during the Ramadan fast. Changes in glycated haemoglobin (HbA1c) and body weight, as well as adherence to treatment, were also assessed.Results:Seventy-two patients were enrolled (vildagliptin, n = 30; SU, n = 41; no treatment, n = 1), of whom 23 (76.7%) and 36 (87.8%), respectively, completed the study. With vildagliptin, there were no HEs or severe HEs, compared with 34 HEs (15 patients, 41.7%) and one severe (grade 2) HE with SU. The mean betwee...

This publication has 24 references indexed in Scilit: